FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246475107> ?p ?o ?g. }

• W4246475107 endingPage "1971" @default.
• W4246475107 startingPage "1971" @default.
• W4246475107 abstract "Abstract Background Prognosis of relapses is severe in elderly multiple myeloma (MM). In recent studies, median survival at progression after 1st line therapy was between 9 and 13 months (T. Facon, Lancet 2007; C. Hulin, J Clin Oncol 2009). Bortezomib (V) plus dexamethasone (D) is a major regimen in the treatment of relapses. Bendamustine (B) demonstrated to be highly active in advanced MM. The IFM 2009-01 trial evaluates the combination of B, V and D in elderly patients with progressive MM on or after 1stline treatment. Methods Phase 2 IFM 2009-01 trial was dedicated to patients older than 65 years in 1st relapse or refractory to 1st line therapy. Inclusion criteria were measurable disease, PS ECOG 0-2, ANC > 1.5x109/l, platelets > 100x109/l, serum creatinine level < 250 mcmol/l, AST and ALT < 3xULN. Pts with prior exposure to bortezomib were excluded. Treatment regimen was B 70 mg/m2 day 1-8, V 1.3 mg/m2 day 1-8-15-22 and D 20 mg day 1-8-15-22 every 28 days. 6 cycles were administered. Responders were assigned to receive maintenance treatment with 6 additional cycles administered 1 month out of 2. Response was evaluated according to IMWG criteria. Response rate was the primary objective. Progression-free survival (PFS), overall survival (OS) and toxicity were secondary end-points. Results From 03/2010 to 07/2011, 73 pts were included. Median age was 75.8 years (range 66-86). Median time from diagnosis to inclusion was 29 months. All pts received only 1 prior line of therapy: Melphalan-Prednisone (MP) in 12, MP-Thalidomide in 42, Lenalidomide-Dexamethasone (LD) in 14, other IMiD-based regimen in 5. Median treatment cycles administered was 7 (1-12). 51 pts (69.8%) achieved at least partial response [best response CR: 10 pts (13.6%), VGPR: 12 pts (16.5%), PR: 29 pts (39.7%), MR: 4 pts (5.5%), SD: 5 pts (6.8%), progression: 12 pts (16.5%), unrelated early death: 1 pt (1.3%)]. Median PFS was 10.8 months (95%CI: 7-18.2 months) and median OS 23 months (15.4-27.5). Adverse prognostic factors for PFS were PS ECOG 2 (p=0.0002), beta 2 microglobulin level > 3.5 mg/l (p=0.0006) and del17p (p=0.01). 26 pts (35.6%) completed the planned 12 cycles of treatment. Cause of treatment discontinuation was progressive MM in 30 pts (41.1%), failure to achieve PR in 5 pts (6.8%), adverse event in 10 pts (13.6%), patient refusal and unknown 1 pt (1.3%) each. 37 pts (50.6%) had died at time of final analysis. Cause of death was MM in 30 pts, sepsis in 5 pts, renal failure in 1 pt and unrelated in 1 pt. Grade 3-4 adverse events were neutropenia: 14 pts (19.1%), thrombocytopenia: 8 pts (10.9%), sepsis: 14 pts (19.1%), gastro-intestinal: 6 pts (8.2%), anaphylaxis: 2 pt (2.7%). Grade 2 peripheral neuropathy occurred in 8 pts (10.%) and grade 3 in 3 pts (4.1%). Conclusions In this elderly population with poor prognosis MM, BVD combination provides a high overall response rate and manageable toxicity. These results compare favourably with those achieved with VD or LD. Disclosures: Roussel: CELGENE: Honoraria; JANSSEN: Honoraria. Leleu:CELGENE: Honoraria; JANSSEN: Honoraria. Cony-Makhoul:BMS: Honoraria. Avet-Loiseau:CELGENE: Honoraria, Speakers Bureau; JANSSEN: Honoraria, Speakers Bureau. Moreau:Janssen: Honoraria; Janssen and Millennium: Membership on an entity’s Board of Directors or advisory committees." @default.
• W4246475107 created "2022-05-12" @default.
• W4246475107 creator A5000455173 @default.
• W4246475107 creator A5000761302 @default.
• W4246475107 creator A5004897638 @default.
• W4246475107 creator A5005909959 @default.
• W4246475107 creator A5020056942 @default.
• W4246475107 creator A5024619647 @default.
• W4246475107 creator A5025168447 @default.
• W4246475107 creator A5026970655 @default.
• W4246475107 creator A5035332783 @default.
• W4246475107 creator A5035919558 @default.
• W4246475107 creator A5038965613 @default.
• W4246475107 creator A5041108107 @default.
• W4246475107 creator A5042776012 @default.
• W4246475107 creator A5043695215 @default.
• W4246475107 creator A5044166434 @default.
• W4246475107 creator A5045552922 @default.
• W4246475107 creator A5048560248 @default.
• W4246475107 creator A5056395107 @default.
• W4246475107 creator A5059590275 @default.
• W4246475107 creator A5060016270 @default.
• W4246475107 creator A5060956664 @default.
• W4246475107 creator A5063422967 @default.
• W4246475107 creator A5069449708 @default.
• W4246475107 creator A5070014603 @default.
• W4246475107 creator A5077081397 @default.
• W4246475107 creator A5079801583 @default.
• W4246475107 creator A5079879759 @default.
• W4246475107 creator A5083854975 @default.
• W4246475107 creator A5089853890 @default.
• W4246475107 date "2013-11-15" @default.
• W4246475107 modified "2023-10-18" @default.
• W4246475107 title "Bendamustine, Bortezomib and Dexamethasone (BVD) In Elderly Patients With Multiple Myeloma In First Relapse: Final Analysis Of The Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial" @default.
• W4246475107 doi "https://doi.org/10.1182/blood.v122.21.1971.1971" @default.
• W4246475107 hasPublicationYear "2013" @default.
• W4246475107 type Work @default.
• W4246475107 citedByCount "1" @default.
• W4246475107 countsByYear W42464751072014 @default.
• W4246475107 crossrefType "journal-article" @default.
• W4246475107 hasAuthorship W4246475107A5000455173 @default.
• W4246475107 hasAuthorship W4246475107A5000761302 @default.
• W4246475107 hasAuthorship W4246475107A5004897638 @default.
• W4246475107 hasAuthorship W4246475107A5005909959 @default.
• W4246475107 hasAuthorship W4246475107A5020056942 @default.
• W4246475107 hasAuthorship W4246475107A5024619647 @default.
• W4246475107 hasAuthorship W4246475107A5025168447 @default.
• W4246475107 hasAuthorship W4246475107A5026970655 @default.
• W4246475107 hasAuthorship W4246475107A5035332783 @default.
• W4246475107 hasAuthorship W4246475107A5035919558 @default.
• W4246475107 hasAuthorship W4246475107A5038965613 @default.
• W4246475107 hasAuthorship W4246475107A5041108107 @default.
• W4246475107 hasAuthorship W4246475107A5042776012 @default.
• W4246475107 hasAuthorship W4246475107A5043695215 @default.
• W4246475107 hasAuthorship W4246475107A5044166434 @default.
• W4246475107 hasAuthorship W4246475107A5045552922 @default.
• W4246475107 hasAuthorship W4246475107A5048560248 @default.
• W4246475107 hasAuthorship W4246475107A5056395107 @default.
• W4246475107 hasAuthorship W4246475107A5059590275 @default.
• W4246475107 hasAuthorship W4246475107A5060016270 @default.
• W4246475107 hasAuthorship W4246475107A5060956664 @default.
• W4246475107 hasAuthorship W4246475107A5063422967 @default.
• W4246475107 hasAuthorship W4246475107A5069449708 @default.
• W4246475107 hasAuthorship W4246475107A5070014603 @default.
• W4246475107 hasAuthorship W4246475107A5077081397 @default.
• W4246475107 hasAuthorship W4246475107A5079801583 @default.
• W4246475107 hasAuthorship W4246475107A5079879759 @default.
• W4246475107 hasAuthorship W4246475107A5083854975 @default.
• W4246475107 hasAuthorship W4246475107A5089853890 @default.
• W4246475107 hasConcept C126322002 @default.
• W4246475107 hasConcept C141071460 @default.
• W4246475107 hasConcept C2776364478 @default.
• W4246475107 hasConcept C2776694085 @default.
• W4246475107 hasConcept C2777063308 @default.
• W4246475107 hasConcept C2777478702 @default.
• W4246475107 hasConcept C2779338263 @default.
• W4246475107 hasConcept C2779709957 @default.
• W4246475107 hasConcept C2780401358 @default.
• W4246475107 hasConcept C2780653079 @default.
• W4246475107 hasConcept C2780739268 @default.
• W4246475107 hasConcept C2781413609 @default.
• W4246475107 hasConcept C2781442060 @default.
• W4246475107 hasConcept C29730261 @default.
• W4246475107 hasConcept C71924100 @default.
• W4246475107 hasConcept C90924648 @default.
• W4246475107 hasConceptScore W4246475107C126322002 @default.
• W4246475107 hasConceptScore W4246475107C141071460 @default.
• W4246475107 hasConceptScore W4246475107C2776364478 @default.
• W4246475107 hasConceptScore W4246475107C2776694085 @default.
• W4246475107 hasConceptScore W4246475107C2777063308 @default.
• W4246475107 hasConceptScore W4246475107C2777478702 @default.
• W4246475107 hasConceptScore W4246475107C2779338263 @default.
• W4246475107 hasConceptScore W4246475107C2779709957 @default.
• W4246475107 hasConceptScore W4246475107C2780401358 @default.
• W4246475107 hasConceptScore W4246475107C2780653079 @default.
• W4246475107 hasConceptScore W4246475107C2780739268 @default.
• W4246475107 hasConceptScore W4246475107C2781413609 @default.
• W4246475107 hasConceptScore W4246475107C2781442060 @default.

• next